Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01185 (
vasopressin
)
23,126
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Total amounts and turnover rates of phosphoinositides and inositol phosphates in normal rat liver and hepatocyte nodules were investigated. Male Wistar rats were injected i.p. with [3H]inositol 18-20 h before killing. The amount of phosphatidylinositol in a homogenate preparation was roughly doubled in the nodules, though levels of polyphosphoinositides were approximately the same. Basal levels of inositol phosphates were the same in nodules and in normal liver. Turnover rates of inositol tris- and tetrakisphosphates were studied after stimulation of intact cells with
vasopressin
for different periods of time (0-5 min). The initial rate of formation of inositol trisphosphate after agonist exposure was fast in both nodular and normal cells. Nodular cells reached peak amount of inositol trisphosphate at 2.5-fold basal levels after 20 s, while normal cells peaked after 40 s at 4.5 times the basal amount. The level of inositol tetrakisphosphate was enhanced very quickly in normal cells, but in the nodular cells there was no increase of this inositol phosphate after
vasopressin
stimulation. To investigate the mechanism of this difference, the activities of inositol 1,4,5-trisphosphate kinase and of
inositol 1,4,5-trisphosphate phosphatase
were studied. Both activities were rapid and equal in nodules and normal liver. The amount of cell surface receptors for
vasopressin
was shown to be one-third in the nodules, as compared to normal cells. This quantitative decrease in receptor number was reflected in lower formation of inositol trisphosphate when stimulated with
vasopressin
, but could not explain the loss of inositol tetrakisphosphate response in nodules. The significance of the reported alterations in second messenger traffic for the growth regulation of nodular cells and for their progression to carcinoma is not yet known, but could add to the nodules being less dependent on growth regulating signals.
...
PMID:Inositol phosphates and phosphoinositides in rat liver nodules. 132 28
In WRK1 cells
vasopressin
stimulates Ins(1,4,5)P3 accumulation and mobilizes intracellular calcium. These two phenomena are transient and exhibit similar time-courses. Experiments performed on intact cells or membrane preparations demonstrate that calcium may also stimulate an accumulation of inositol phosphates. This suggests a possible positive feedback regulation of the primary accumulation of Ins(1,4,5)P3 induced by
vasopressin
. In order to test such a possibility we studied the
vasopressin
-induced Ins(1,4,5)P3 accumulation, where intracellular calcium mobilization is artificially suppressed by incubating the cells with EGTA in the presence of ionomycin. Under these conditions the accumulation of Ins(1,4,5)P3 induced by 1 microM
vasopressin
is inhibited by around 50% when measured 5 s after stimulation. This inhibition is not due to an alteration of the VIa
vasopressin
receptor binding properties, a reduction of the amount of substrate available for the phospholipase C, a stimulation of the
Ins(1,4,5)P3 5-phosphatase
or an activation of the Ins(1,4,5,)P3 kinase. It is more likely the consequence of the suppression of calcium wave generated by Ins(1,4,5)P3 which may in its turn stimulate a phospholipase C. Different arguments favour this hypothesis: (1) calcium at an intracellular physiological concentration (0.1-1 microM) is able to stimulate a phospholipase C; (2) artificially increasing the [Ca2+]i inside the WRK1 cell induces an accumulation of Ins(1,4,5)P3; and (3) the time-course of the inhibition of Ins(1,4,5)P3 accumulation induced by an EGTA/ionomycin treatment correlates well with that of the calcium mobilization. Altogether these results suggest that Ins(1,4,5)P3 accumulation in WRK1 cells may result from two distinct mechanisms: a direct
vasopressin
receptor-mediated PLC activation which is independent of calcium and a calcium-mediated PLC activation related to the intracellular calcium mobilization.
...
PMID:Positive feedback regulation of phospholipase C by vasopressin-induced calcium mobilization in WRK1 cells. 217 21
We have augmented our previous studies [Storey, Shears, Kirk & Michell (1984) Nature (London) 312, 374-376] on the subcellular location and properties of Ins(1,4,5)P3 (inositol 1,4,5-trisphosphate) phosphatases in rat liver and human erythrocytes. We also investigate Ins(1,3,4)P3 (inositol 1,3,4-trisphosphate) metabolism by rat liver. Membrane-bound and cytosolic Ins(1,4,5)P3 phosphatases both attack the 5-phosphate. The membrane-bound enzyme is located on the inner face of the plasma membrane, and there is little or no activity associated with Golgi apparatus. Cytosolic
Ins(1,4,5)P3 5-phosphatase
(Mr 77,000) was separated by gel filtration from Ins(1,4)P2 (inositol 1,4-bisphosphate) and inositol 1-phosphate phosphatases (Mr 54,000).
Ins(1,4,5)P3 5-phosphatase
activity in hepatocytes was unaffected by treatment of the cells with insulin,
vasopressin
, glucagon or dibutyryl cyclic AMP.
Ins(1,4,5)P3 5-phosphatase
activity in cell homogenates was unaffected by changes in [Ca2+] from 0.1 to 2 microM. After centrifugation of a liver homogenate at 100,000 g, Ins(1,3,4)P3 phosphatase activity was largely confined to the supernatant. The sum of the activities in the supernatant and the pellet exceeded that in the original homogenate. When these fractions were recombined, Ins(1,3,4)P3 phosphatase activity was restored to that observed in unfractionated homogenate. Ins(1,3,4)P3 was produced from Ins(1,3,4,5)P4 (inositol 1,3,4,5-tetrakisphosphate) and was metabolized to a novel InsP2 that was the 3,4-isomer. Ins(1,3,4)P3 phosphatase activity was not changed by 50 mM-Li+ or 0.07 mM-Ins(1,4)P2 alone, but when added together these agents inhibited Ins(1,3,4)P3 metabolism. In Li+-treated and
vasopressin
-stimulated hepatocytes, Ins(1,4)P2 may reach concentrations sufficient to inhibit Ins(1,3,4)P3 metabolism, with little effect on Ins(1,4,5)P3 hydrolysis.
...
PMID:Dephosphorylation of myo-inositol 1,4,5-trisphosphate and myo-inositol 1,3,4-triphosphate. 303 88